老年胶质母细胞瘤手术中外科医生经验的影响:一项多中心回顾性队列研究
该多中心回顾性队列研究纳入198例≥65岁胶质母细胞瘤患者,分析外科医生经验与总生存期、切除程度及手术相关并发症的关系。结果显示,医生终身的胶质瘤手术经验与总生存期(P=0.693)、切除程度(P=0.693)及手术相关并发症(P=0.435)均无相关性。辅助治疗是改善总生存期的唯一显著预测因素(P<0.001;HR=0.064,95%CI 0.028-0.144)。
要点
- 在学术教学医院中,经验较少的神外医生对老年胶质母细胞瘤患者可获得相似的手术结果和结局。
- 辅助治疗与改善的总生存期相关(P<0.001),是多变量分析中唯一显著预测因素。
- 发生手术相关并发症的患者接受辅助治疗的可能性更低(P=0.002)。
核心结论
- 在学术教学医院环境下,经验较少的神经外科医生在老年胶质母细胞瘤患者中可获得相似的手术结果和结局。
- 辅助治疗和避免手术相关并发症对于该人群获得治疗获益至关重要。
研究设计与样本
- 多中心回顾性队列研究,纳入两家学术中心接受肿瘤切除的≥65岁胶质母细胞瘤患者198例。
- 外科医生经验通过三种方式量化:既往胶质瘤手术总数(终身经验)、过去五年手术量(中期经验)和过去两年手术量(短期经验)。
主要发现
- 198例患者中位年龄73.0岁,中位术前KPS 80,IDH野生型状态96.5%。
- 中位总生存期10.0个月(95%CI 8.0-12.0),中位切除程度89.4%,手术相关并发症发生率19.7%。
- 外科医生终身经验与总生存期(P=0.693)、切除程度(P=0.693)及手术相关并发症(P=0.435)均无相关性。
- 辅助治疗与改善的总生存期相关(P<0.001);发生手术相关并发症的患者接受辅助治疗的可能性更低(P=0.002)。
- 多变量分析中,辅助治疗是改善总生存期的唯一显著预测因素(P<0.001;HR=0.064,95%CI 0.028-0.144)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the impact of individual surgeon experience on overall survival (OS), extent of resection (EOR) and surgery-related morbidity in elderly patients with glioblastoma (GBM), we performed a retrospective case-by-case analysis. METHODS: GBM patients aged ≥ 65 years who underwent tumor resection at two academic centers were analyzed. The experience of each neurosurgeon was quantified in three ways: (1) total number of previously performed glioma surgeries (lifetime experience); (2) number of surgeries performed in the previous five years (medium-term experience) and (3) in the last two years (short-term experience). Surgeon experience data was correlated with survival (OS) and surrogate parameters for surgical quality (EOR, morbidity). RESULTS: 198 GBM patients (median age 73.0 years, median preoperative KPS 80, IDH-wildtype status 96.5%) were included. Median OS was 10.0 months (95% CI 8.0-12.0); median EOR was 89.4%. Surgery-related morbidity affected 19.7% patients. No correlations of lifetime surgeon experience with OS (P = .693), EOR (P = .693), and surgery-related morbidity (P = .435) were identified. Adjuvant therapy was associated with improved OS (P < .001); patients with surgery-related morbidity were less likely to receive adjuvant treatment (P = .002). In multivariable testing, adjuvant therapy (P < .001; HR = 0.064, 95%CI 0.028-0.144) remained the only significant predictor for improved OS. CONCLUSION: Less experienced neurosurgeons achieve similar surgical results and outcome in elderly GBM patients within the setting of academic teaching hospitals. Adjuvant treatment and avoidance of surgery-related morbidity are crucial for generating a treatment benefit for this cohort.
引用
- Pöppe JP, Machegger L, Steinbacher J, et al. Surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study. J Neurooncol. 2023. PMID: 36719614. doi:10.1007/s11060-023-04252-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。